Knowing stock market today at a glance

Novo Nordisk Shares Soar 7.65% on Strong Q1 Earnings

Mover TrackerWednesday, May 7, 2025 5:12 am ET

1min read

On May 7, 2025, Novo Nordisk's stock surged by 7.65% in pre-market trading, reflecting strong investor confidence in the company's recent performance and future prospects.

Novo Nordisk reported robust financial results for the first quarter of 2025, with global sales reaching 780.87 billion Danish kroner, driven primarily by its diabetes and obesity treatment products. The company's diabetes business generated 550.44 billion Danish kroner in sales, with GLP-1 products and insulin contributing significantly to this growth. Notably, the GLP-1-based diabetes treatment portfolio, including Ozempic, Rybelsus, and Victoza, achieved a combined sales figure of 395.74 billion Danish kroner, marking an 11% year-over-year increase.

In the obesity treatment segment, Wegovy and Saxenda recorded a combined sales figure of 184.24 billion Danish kroner, with Wegovy alone contributing 173.6 billion Danish kroner, an 83% year-over-year increase. The company's flagship drug, semaglutide, which is available in multiple formulations including Ozempic, Rybelsus, and Wegovy, generated a total of 557.76 billion Danish kroner in sales, accounting for 71% of the company's total revenue.

Novo Nordisk's rare disease business also showed moderate growth, with sales reaching 46.19 billion Danish kroner, a 3% year-over-year increase. In China, the company reported significant growth, with revenue reaching 56.22 billion Danish kroner, a 25% year-over-year increase, driven by strong demand for its diabetes and obesity treatment products.

The company also announced positive results from the REDEFINE 2 Phase III clinical trial for CagriSema, a combination drug of cagrilintide and semaglutide, which demonstrated a 15.7% average weight loss in patients with obesity or overweight and type 2 diabetes. Novo Nordisk plans to submit a marketing application for CagriSema in the first quarter of 2026.

Additionally, Novo Nordisk is advancing other research and development projects, including a 25 mg oral semaglutide for obesity treatment, which has been submitted to the U.S. FDA for regulatory review, and a weekly injection of 2.4 mg semaglutide for the treatment of MASH (metabolic-associated steatohepatitis), which has been submitted for approval in the EU and the U.S. The company is leveraging its GLP-1 platform to develop a comprehensive product portfolio addressing high-growth indications such as diabetes, obesity, and MASH.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.